TORONTO, April 15, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide an update on its psychedelic product programs as it relates to the clinical and commercial development of ketamine and the research and development of proprietary microneedle patch delivery systems for…


Previous articleAlbert Labs Appoints Mackie Research As Lead Agent For Private Placement Of Proceeds Up To $4 Million Pre-RTO
Next articlePTSF55 – Creativity, Group Ceremony, and Astral Projection